On Wednesday, three pharmaceutical executives, including former Celgene CEO Mark Alles, testified on drug pricing for the House Oversight Committee. While at the company, Alles saw a massive increase in the price of the cancer drug Revlimid — and Porter broke down just what it got Alles in return.
Porter started her takedown by asking Alles if he knew what a Revlimid pill cost in 2005: $215, she reminded him with the help of a whiteboard. And by the time Alles left the company late last year, after its sale to Bristol-Myers Squibb, a single Revlimid pill cost $763."Did the drug get substantially more effective in that time? Did cancer patients need fewer pills?" Porter questioned, trying to figure out why Celgene upped the price.
Porter then moved on to tear apart the $13 million Alles made in 2017 as Celgene's CEO."It's 200 times the average American's income and 360 times what the average senior makes on Social Security," Porter noted. She then reminded Alles just how he made"half a million dollars, personally, just by tripling the price of Revlimid.
How many patients lost their lives because they couldn't afford this medicine? Here's our conversation: pic.twitter.com/mkke6y9tnw7 savagely funny cartoons about the Trump tax revelationsMarvel casts newcomer in the role of its 1st Muslim superhero, Ms. Marvel